Radiopharm Theranostics Ltd
Radiopharm Theranostics Limited is an Australia-based clinical-stage radiotherapeutics company developing a platform of radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need.
The business
Radiopharm Theranostics Limited is an Australia-based clinical-stage radiotherapeutics company developing a platform of radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. The Company has a pipeline of highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase II and three Phase I trials in a variety of solid tumor cancers including lung, breast, and brain. Its technologies include Nano-mAbs, Pivalate, AVB6 Integrin, PSA-mAb, and PTPu. Nano-mAbs is a novel radiopharmaceutical platform made using genetic engineered camelid derived single domain antibodies (sdAb) labelled with a radioisotope of therapeutic radiation. Pivalate is an 18F-FPIA radiotracer, based on a short chain carbohydrate which utilizes the early steps of fatty acid oxidation.
Small Caps Research
No research on Radiopharm Theranostics Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise RAD based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Starpharma and Radiopharm Theranostics Partner to Develop Novel Radiotherapy Asset
Starpharma Holdings (ASX: SPL) has entered into a research and option partnership with Radiopharm Theranostics (ASX: RAD) to develop and manufacture a dendrimer drug conjugate incorporating a radiopharmaceutical molecule to target certain cancers. The partnership, which follows six months of preliminary research under Starpharma’s Star Navigator drug development program, will see Radiopharm pay Starpharma a $500,000 for an […]
Radiopharm Theranostics Receives FDA Investigational New Drug Clearance for RV-01 Cancer Therapy
Radiopharm Theranostics (ASX: RAD) has received investigational new drug clearance from the US Food and Drug Administration (FDA) for therapeutic candidate Betabart (RV-01). RV-01 targets the B7H3 immune checkpoint molecule that plays a role in cancer development and progression. The FDA clearance will now allow the company to initiate a first-in-human Phase 1 clinical trial […]
Radiopharm Theranostics earns FDA approval for brain metastasis imaging agent RAD 101
Clinical-stage biopharmaceutical company Radiopharm Theranostics (ASX: RAD) has received clearance from the US Food and Drug Administration (FDA) for an investigational new drug (IND) application relating to F18-Pivalate (RAD 101). RAD 101 is a proprietary imaging agent currently under clinical investigation for the detection and characterisation of brain metastases. Labelled with the radioisotope F18, pivalate […]
Radiopharm Theranostics secures $70m in funding with major stake from Lantheus Holdings
US-based radiopharmaceuticals industry leader Lantheus Holdings has agreed to make a hefty investment into a $70 million equity raising by Australian biotech Radiopharm Theranostics (ASX: RAD). The funds raised through share placement will be used by Radiopharm for manufacturing and clinical trials of its oncology drugs over the next two years. Long-term commitment Lantheus has […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.